Immunovant, Inc. (IMVT)
| Market Cap | 485.83M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -156.73M |
| Shares Out | 116.51M |
| EPS (ttm) | -1.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 770,377 |
| Open | 4.05 |
| Previous Close | 4.00 |
| Day's Range | 3.99 - 4.25 |
| 52-Week Range | 3.15 - 11.61 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 10.20 (+144.6%) |
| Earnings Date | Aug 8, 2022 |
About IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquar... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for IMVT stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 144.60% from the latest price.
News
Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development
Immunovant (IMVT) remains focused on developing lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. Lack of other pipeline candidate remains a concern.
Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED
Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.
Immunovant To Start Pivotal Batoclimab Trials In Thyroid Eye Disease Later This Year
Immunovant Inc (NASDAQ: IMVT) has aligned with the FDA Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 trials to evaluate batoclimab in thyroid eye disease (TED). Immunova...
Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and ...
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announ...
Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announ...
Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announc...
Immunovant to Present at the UBS Global Healthcare Conference on May 23rd
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announc...
Immunovant to Host Virtual R&D Day on March 30, 2022
Event will feature six key opinion leaders with expertise in thyroid eye disease, myasthenia gravis, warm autoimmune hemolytic anemia, and cholesterol management Event will feature six key opinion leade...
Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference
NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announ...
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3
Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.
Immunovant Reports Financial Results for the Quarter Ended December 31, 2021
Company Ended the Quarter With Cash of Approximately $527.0 Million Company Ended the Quarter With Cash of Approximately $527.0 Million
Immunovant Appoints Mark Levine as Chief Legal Officer
NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced th...
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announ...
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in th...
NEW YORK, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced th...
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announ...
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2
Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
Immunovant Reports Financial Results for the Quarter Ended September 30, 2021
Company Ended the Quarter With Cash of Approximately $559 Million Company Ended the Quarter With Cash of Approximately $559 Million
Immunovant to Participate in Roivant R&D Day 2021
NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today annou...
Immunovant, Inc. (IMVT) Up 9.3% Since Last Earnings Report: Can It Continue?
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q1
Immunovant's (IMVT) earnings miss estimates in first-quarter fiscal 2022 (ended Jun 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
Immunovant Reports Financial Results for the Quarter Ended June 30, 2021
Company Ended the Quarter With Cash of Approximately $379 Million and Subsequently Received a Direct Investment of $200 Million from Roivant Company Ended the Quarter With Cash of Approximately $379 Mil...
Immunovant to Report Financial Results for Quarter Ended June 30, 2021
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announ...
Why Shares of Immunovant Are Down Almost 10% This Afternoon
An analyst note is extending yesterday's sell-off.
SPAC engineering reaches new heights as scrapped deal sends pharma firm's stock plunging 36%
Drugmaker Roviant Sciences had been plotting a novel take on the popular SPAC deal, according to a report from Bloomberg.
Why Shares of Immunovant Are Tanking Today
Shareholders are throwing in the towel after not getting the deal they were expecting.